Airway-Rehydrating Agents for the Treatment of Cystic Fibrosis: Past,Present,and Future

Abstract

Spanish

French

Objective

To review and evaluate airway-rehydrating agents used for the treatment of cystic fibrosis (CF).

Data Sources:

Literature was retrieved through MEDLINE (1977-August 2010), Cochrane Library, and International Pharmaceutical Abstracts (1977-August 2010). Search terms used included hypertonic saline, inhaled mannitol, denufosol, Moli 1901, lancovutide, and cystic fibrosis. Reference citations from selected articles were reviewed.

Study Selection And Data Extraction:

All articles published in English identified from the data sources were evaluated for inclusion. Clinical trials in humans and relevant review articles were evaluated for each airway-rehydrating agent,

Data Synthesis:

Use of airway-rehydrating agents for the treatment of CF is an expanding area. Hypertonic saline (7% NaCl) is currently the only commercially available airway-rehydrating agent recommended for chronic therapy in patients with CF and is being evaluated in younger patients. Inhaled mannitol is an investigational dry-powder inhalation agent that improves mucus clearance in a similar manner to hypertonic saline and produced a statistically significant increase in forced expiratory volume in 1 second in a Phase 3 trial. Denufosol, a P2Y₂ agonist, rehydrates the airway surface liquid bypassing the basic CF transmembrane conductance regulator (CFTR) protein defect. It produces improvement in pulmonary function and is being further evaluated in a Phase 3 trial. Lancovutide (Moli 1901) is an investigation at agent in early-phase trials that activates a calcium-dependent chloride channel, allowing chloride to enter the airway.

Conclusions:

Hypertonic saline is the primary airway-rehydrating agent used in the treatment of CF. Inhaled mannitol may become an alternative to hypertonic saline since it is faster and easier to administer. It remains unclear whether Denufosol and lancovutide will be synergistic or antagonistic with hypertonic saline. Both agents have a unique mechanism of action that bypasses the basic CFTR defect.

Keywords

cystic fibrosis denufosol hypertonic saline inhaled mannitol lancovutide,Moli1901

Get full access to this article

View all access options for this article.

References

O'Sullivan

, Freedman

. Cystic fibrosis. Lancet 2009; 373:1891–904. DOI 10.1016/S0140-6736(09)60327-5

Flume

, O'Sullivan

, Robinson

. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176:957–69. DOI 10.1164/rccm.200705-664OC

Marks

. Airway clearance devices in cystic fibrosis. Paediatr Respir Rev 2007; 8:17–23. DOI 10.1016/j.prrv2007.02.003

Flume

, Robinson

, O'Sullivan

. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009; 54:522–37.

Millis

, Young

, Kulczycki

. Validation of therapeutic bronchoscopic bronchial washing in cystic fibrosis. Chest 1977; 71:508–13. DOI 10.1378/chest.71.4.508

Ratjen

, Bush

. Amiloride: still a viable treatment option in cystic fibrosis? Am J Respir Crit Care Med 2008; 178:1191–3.

Hirsh

, Zhamg

, Zamurs

. Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl-N-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2008; 325:77–88. DOI 10.1124/jpet.107.130443

Jones

, Helm

. Emerging treatments in cystic fibrosis. Drugs 2009; 69:1903–10.

Fibrosis Foundation. A “surf session” for babies? http://www.cff.org/aboutCFFoundation/Publications/connections/archive/JuIyAugust2009/Hypertonic-Saline.cfm (accessed 2010 Aug 29).

10.

Taylor

, Kuhn

. Hypertonic saline treatment of cystic fibrosis. Ann Pharmacother 2007; 41:481–4. DOI 10.1345/aph.1H425

11.

Tarran

, Donaldson

, Boucher

. Rationale for hypertonic saline therapy for cystic fibrosis lung disease. Semin Respir Crit Care Med 2007; 28:295–302. DOI 10.1055/S-2007-981650

12.

Wark

, McDonald

. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2009: CD001506. DOI 10.1002/14651858.CD001506.pub313

13.

Havasi

, Hurst

, Briles

. Inhibitory effects of hypertonic saline on P. aeruginosa motility. J Cyst Fibros 2008; 7:267–9. DOI 10.1016/j.jcf.2007.11.009

14.

Robinson

, Hemming

, Regnis

. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997; 52:900–3.

15.

Eng

, Morton

, Douglass

, Riedler

, Wilson

, Robertson

. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. PediatrPulmonol 1996; 21:77–83.

16.

Donaldson

, Bennett

, Zeman

, Knowles

, Tarran

, Boucher

. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354:241–50.

17.

Elkins

, Robinson

, Rose

. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354:229–40. DOI 10.10567NEJMoa04390018

18.

Dellon

, Donaldson

, Johnson

, Davis

. Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis. Pediatr Pulmonol 2008; 43:1100–6. DOI 10.1002/ppul.20909

19.

Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS). http://www.clinicaltrials.gov/ct2/show/NCT00709280?term=hypertonic+saline&rank=38 (accessed 2010 Jan 29).

20.

7% Pre-mixed hypertonic saline flyer, www.cfservicespharmacy.com (accessed 2010 Mar 9).

21.

Anderson

, Brannan

, Spring

. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med 1997; 156:758–65.

22.

Daviskas

, Anderson

, Eberl

, Chan

, Bautovich

. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999; 159:1843–8.

23.

Jaques

, Daviskas

, Turton

. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008; 133:1388–96. DOI 10.1378/chest.07-2294

24.

Robinson

, Daviskas

, Eberl

. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999; 14:678–85.

25.

Minasian

, Wallis

, Metcalfe

, Bush

. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. Thorax 2010; 65:51–6. DOI 10.1136/thX.2009.116970

26.

Goldman

, Anderson

, Stolzenberg

, Kari

, Zasloff

, Wilson

. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997; 88:553–60.

27.

Smith

, Travis

, Greenberg

, Welsh

. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85:229–36.

28.

Daviskas

, Anderson

, Jaques

, Charlton

. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest 2009; 137:861–8. DOI 10.1378/chest.09-2017

29.

Bilton

, Robinson

, Cooper

, Charlton

. Randomized, double blind, placebo-controlled Phase HI study of inhaled dry powder mannitol (Bronchitol) in CF. Pediatr Pulmonol 2009; 44(suppl 32):286.

30.

Minasian

, Wallis

, Metcalfe

, Bush

. Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis. Pediatr Pulmonol 2008; 43:1078–84. DOI 10.1002/ppul.20903

31.

Daviskas

, Anderson

, Eberl

, Young

. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur Respir J 2008; 31:765–72. DOI 10.1183/09031936.00119707

32.

Yerxa

, Sabater

, Davis

. Pharmacology of INS37217 [P(1)-(uridine 5')P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis. J Pharmacol Exp Ther 2002; 302:871–80. DOI 10.1124/jpet.102.035485

33.

Kellerman

, Rossi Mospan

, Engels

, Schaberg

, Gorden

, Smiley

. Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3. Pulm Pharmacol Ther 2008; 21:600–7. DOI 10.1016/j.pupt.2007.12.003

34.

Deterding

, Retsch-Bogart

, Milgram

. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y₂ receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderatecystic fibrosis. Pediatr Pulmonol 2005; 39:339–48. DOI 10.1002/ppul.20192

35.

Smiley

, Rossi

, Mathews

. Denufosol tetrasodium inhalation solution: results from two phase 2 trials in CF patients with mild to moderate lung disease (abstract 47). J Cyst Fibros 2006; 5:S11.

36.

Deterding

, Lavange

, Engels

. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med 2007; 176:362–9. DOI 10.1164/rccm.200608-1238OC

37.

Moss

, Anbar

, Wilmott

. Phase 3 study of denufosol tetrasodium for the treatment of cystic fibrosis. Presented at: American Thoracic Society 2009 International Conference, San Diego, CA, May 15-20, 2009.

38.

Chines

, Boucher

. Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis. Curr Opin Pharmacol 2008; 8:292–9. DOI 10.1016/j.coph.2008.04.006

39.

Zeitlin

, Boyle

, Guggino

, Molina

. A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest 2004; 125:143–9.

40.

Grasemann

, Stehling

, Brunar

. Inhalation of Moli1901 in patients with cystic fibrosis. Chest 2007; 131:1461–6. DOI 10.1378/chest.06-2085

41.

Studies of lancovutide in cystic fibrosis. http://www.lantibio.com/Iantibio_moli1901_cf_studies.htm (accessed 2010 Mar 8).

42.

Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults with Cystic Fibrosis, http://www.clinicaltrials.gov/ct2/show/NCT00671736?term=lancovutide&rank=l (accessed 2010 Mar 8).